Acurx price target lowered to $5 from $14 at Alliance Global Partners

Alliance Global Partners lowered the firm’s price target on Acurx (ACXP) to $5 from $14 and keeps a Buy rating on the shares after the company reported Q4 results and provided clinical development updates for its lead compound ibezapolstat for the treatment of c. difficile infections. While the firm remains positive on the upcoming 2025 developments, it adjusted its price target given its new expectations for potential launch and the funding/partnership needs for ibezapolstat to come to market.